Sanofi details R&D strategy

Sanofi (Euronext:SAN; NYSE:SNY) highlighted its R&D road map at its analyst meeting Dec. 13. The pharma plans to shift its focus to biologics from small molecules, to multi-targeting compounds from mono-targeting ones and to proprietary assets from

Read the full 373 word article

User Sign In